I think that is inaccurate. I believe the IRB safety study is due for completion by the end of Q1 which would be in two weeks or so. Once completed it would probably be announced. That is a potential big catalyst for us. That safety study could make the cream eligible for compounding in pharmacies, allowing it to be sold as a drug. It would also be a necessary component for any licensing deals IMO.
Very good points. And why would they go to the trouble and expense of recruiting world class talent if they thought there were problems or if they didn't have something good in the works? The answer is; they wouldn't.